Peptide
Abaloparatide
Abaloparatide (Tymlos) is an FDA-approved (2017) anabolic osteoporosis drug, NOT a supplement. It's a synthetic PTHrP analog that builds bone more effectively than older therapies. A-GRADE evidence for vertebral fracture reduction (86%), non-vertebral fractures (43%), and BMD increases. Requires daily subcutaneous injection. PRESCRIPTION ONLY - included here for informational purposes. Used in high-risk postmenopausal women and men. Has faster receptor kinetics than teriparatide with possibly better safety profile.
- Updated
- How we grade
- 39 studies cited
Research notice. This page is for education and research. Peptides may not be FDA-approved for human use and may only be legally available for research. Talk to a qualified clinician before considering any peptide.
- Best evidence
- Grade A
- Conditions studied
- 1
- Outcomes
- 9
- Graded outcomes
- 5202
Evidence by condition
- Strong
- Moderate
- Limited
- Very limited
General
Key findings
- Lumbar Spine BMDImproves (the measure goes up)
- Vertebral Fracture RiskImproves (the measure goes down)
- Non-Vertebral Fracture RiskImproves (the measure goes down)
Studies cited
39 studies from PubMed
- Effect of abaloparatide on fracture incidence and bone mineral density in postmenopausal women with osteoporosis at highest risk for fracture
- Efficacy and safety of abaloparatide, denosumab, teriparatide, oral bisphosphonates, and intravenous bisphosphonates in the treatment of male osteoporosis: a systematic review and Bayesian network meta-analysis.
- Abaloparatide Enhances Bone Regeneration in Extraction Socket Dental Implant Defects: An Experimental In Vivo Study.
- Osteoporosis: A Review.
- The Safety and Efficacy of Abaloparatide on Postmenopausal Osteoporosis: A Systematic Review and Meta-analysis.
- Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
- Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials.
- Efficacy and Safety of Transdermal Abaloparatide in Postmenopausal Women with Osteoporosis: A Randomized Study.
- Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis.
- Abaloparatide dose-dependently increases bone mineral density in postmenopausal women with osteoporosis: a phase 2 study.
- The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial
- Diagnosis and Management of Osteoporosis in Advanced Kidney Disease: A Review.
- Abaloparatide Increases Lumbar Spine and Hip BMD in Japanese Patients With Osteoporosis: The Phase 3 ACTIVE-J Study.
- Abaloparatide: A review of preclinical and clinical studies
- Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women With Osteoporosis
- Abaloparatide and the Spine: A Narrative Review.
- Abaloparatide, the second generation osteoanabolic drug: Molecular mechanisms underlying its advantages over the first-in-class teriparatide
- ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis
- Abaloparatide, a novel osteoanabolic PTHrP analog, increases cortical and trabecular bone mass and architecture in orchiectomized rats by increasing bone formation without increasing bone resorption.
- Abaloparatide: A new pharmacological option for osteoporosis.
- Osteoporosis.
- Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability.
- Efficacy and safety of abaloparatide for the treatment of post-menopausal osteoporosis.
- Precisely Controlled Delivery of Abaloparatide through Injectable Hydrogel to Promote Bone Regeneration.
- Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial.
- Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis
- ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis.
- Abaloparatide for the treatment of postmenopausal osteoporosis.
- Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial.
- Abaloparatide: Review of a Next-Generation Parathyroid Hormone Agonist.
- Effects of Abaloparatide-SC on Fractures and Bone Mineral Density in Subgroups of Postmenopausal Women With Osteoporosis and Varying Baseline Risk Factors
- Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
- Abaloparatide for the treatment of postmenopausal osteoporosis
- Abaloparatide: First Global Approval
- Abaloparatide: Recombinant human PTHrP (1-34) anabolic therapy for osteoporosis.
- Abaloparatide (Tymlos) for postmenopausal osteoporosis.
- Profile of Abaloparatide and Its Potential in the Treatment of Postmenopausal Osteoporosis.
- Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial
- Osteoporosis: Clinical Evaluation.